Company profile
MC2 Therapeutics
Privately held: no public share price
Assets
(2 total)
2Total Assets
1Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
| Approved | Vitamin D receptor + Glucocorticoid receptorSmall molecule | Psoriasis | |
| Phase 2 | Topical dipeptide (alanyl-glutamine)Small molecule | Indication not yet linked |
Upcoming events
Research
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.